Clinical Trial

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the clinical efficacy of HLX22 in combination with HLX87 as first-line treatment in patients with HER2-positive recurrent or metastatic breast cancer
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-12-08; most recent amendment 2026-03-17.
Status change: Not Yet Recruiting → Recruiting 2026-03-17
Trial Details
NCT Number NCT07294508
Lead Sponsor Shanghai Henlius Biotech
Conditions HER2 + Breast Cancer
Enrollment 706 participants
Start Date 2026-02-27
Primary Completion 2028-01-15 (estimated)
Study Completion 2030-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-20